Clik here to view.
ViiV Healthcare submits regulatory applications for HIV two-drug regimen
GSK and ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi Limited as shareholders, have announced regulatory submissions to the European Medicines...
View ArticleClik here to view.
Pfizer collaboration to reduce injectable contraceptive price
“New innovations in contraceptive technology are needed to expand the number of methods available to women and adolescents so they can take charge of their health and their futures.” Pfizer, the Bill...
View ArticleClik here to view.
Sangamo and Pfizer to collaborate on Haemophilia A gene therapy
Sangamo Therapeutics and Pfizer have announced an exclusive, global collaboration and license agreement for the development and commercialisation of gene therapy programs for Haemophilia A, including...
View ArticleClik here to view.
Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research
Our current system of medicines regulation offers an outstanding example of European cooperation at its finest. By joining forces across nation states, bringing together the best and brightest minds...
View ArticleClik here to view.
Pfizer’s Phase III study to treat hospital-acquired pneumonia a success
Positive results of Pfizer‘s REPROVE study showed that patients diagnosed with hospital-acquired pneumonia (HAP), treated with Zavicefta (ceftazidime-avibactam), a novel combination antibiotic for the...
View ArticleClik here to view.
2017 Pipelines: Drugs to watch
Eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$900 billion by 2021, according to consensus sales forecast data from Clarivate Analytics Cortellis Competitive...
View ArticleClik here to view.
Injectable drug delivery market worth US$624.50 billion by 2021
According to a new market research report published by MarketsandMarkets, the global injectable drug delivery market, in terms of value, is projected to reach US$624.50 Billion by 2021 from US$362.38...
View ArticleClik here to view.
Celltrion Healthcare & Pfizer’s biosimilar shows positive results in Crohn’s...
Celltrion Healthcare and Pfizer presented the primary outcome from its pivotal randomised controlled trial of CT-P13 (biosimilar of infliximab) in Crohn’s disease. The data indicate that the safety and...
View ArticleClik here to view.
The Top 21…wealthiest pharma companies
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the...
View ArticleClik here to view.
Pfizer’s breast cancer drug too expensive for NHS
The National Institute for Health and Care Excellence (NICE) has today published draft guidance which does not recommend breast cancer drug palbociclib (Ibrance, Pfizer) for routine funding on the NHS....
View ArticleClik here to view.
Pfizer fined £85 million for 2600% drug price increase to NHS
The Competition and Markets Authority has imposed a record £84.2 million fine on the pharmaceutical manufacturer Pfizer, and a £5.2 million fine on the distributor Flynn Pharma after finding that each...
View ArticleClik here to view.
ViiV Healthcare to evaluate injectable HIV treatment
ViiV Healthcare, owned by GSK with Pfizer and Shionogi as shareholders, has started two Phase III studies designed to evaluate an investigational long-acting, injectable regimen of cabotegravir (ViiV...
View ArticleClik here to view.
Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet...
Live: 8 December 2016 | 15:00 GMT Register now ABOUT THIS WEBINAR Pfizer has been studying the use of MicroNIR for several years and has been working to develop fit-for-purpose packages for specific...
View ArticleClik here to view.
EU approval for Pfizer’s non-small cell lung cancer drug
The European Commission has approved Pfizer’s xalkori (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).In the EU, xalkori is also indicated for...
View ArticleClik here to view.
Re-evaluating the Cancer Drugs Fund: Out with the old, in with the new
Originally introduced in 2011, The Cancer Drugs Fund (CDF) was established by the coalition Government in order to provide a means by which NHS patients in England could get cancer drugs that were not...
View ArticleClik here to view.
Pfizer to acquire AstraZeneca’s anti-infective business
Pfizer has entered into an agreement with AstraZeneca to acquire the development and commercialisation rights to its late-stage small molecule anti-infective business.The agreement includes the rights...
View ArticleClik here to view.
NICE recommends Pfizer’s lung cancer drug after price drop
After Pfizer further discounted the drug, the National Institute for Health and Care Excellence (NICE) reversed their previous decision, issuing a second draft guidance recommending crizotinib...
View ArticleClik here to view.
Global dual-drug trial aims to advance HIV treatment
ViiV Healthcare is undertaking studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus...
View ArticleClik here to view.
Pfizer’s Vyndaqel a success for rare disease
Pfizer have released data analysis from three studies of Vyndaqel, a treatment for patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP).The analysis, which included patients with...
View ArticleClik here to view.
FDA approves label expansion for Pfizer’s Prevnar 13
The US Food and Drug Administration (FDA) has approved an expanded age indication for Pfizer’s Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).Prevnar 13 is now...
View Article![BLACKPINK – DEADLINE – EP [iTunes Plus M4A]](http://is1-ssl.mzstatic.com/image/thumb/Video211/v4/de/b3/b1/deb3b1d4-ba28-22e8-2428-ef97617b2a4b/90d54d743002a6d66308f217cd867947_Preview_Image_Intermediate_nonvideo_sdr_426725135_2574858051.png/316x316bb.webp)
